An Intergenerational Precision Medicine Research Program for the Study of Factor VIII Immunogenicity in Severe Hemophilia A: Hemophilia A Analytical Cohort Research Program (UG3/UH3 Clinical Trial Not Allowed)
The summary for the An Intergenerational Precision Medicine Research Program for the Study of Factor VIII Immunogenicity in Severe Hemophilia A: Hemophilia A Analytical Cohort Research Program (UG3/UH3 Clinical Trial Not Allowed) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
An Intergenerational Precision Medicine Research Program for the Study of Factor VIII Immunogenicity in Severe Hemophilia A: Hemophilia A Analytical Cohort Research Program (UG3/UH3 Clinical Trial Not Allowed): The purpose of this FOA is to support applications that propose the establishment of a Hemophilia A Analytical Cohort Research Program (HARP) that will: 1) collaborate with an established consortium of clinical centers to support the recruitment, enrollment, and follow-up of an antenatal/ neonatal/ pediatric cohort in severe hemophilia A; 2) provide data management, laboratory, and biospecimen support necessary for the establishment of a unique and sharable biospecimen resource annotated with robust intergenerational clinical and demographic data to enable future studies of FVIII immunogenicity; and 3) develop and implement protocols and procedures to conduct hypothesis-driven research studies utilizing data and biospecimens from the antenatal/neonatal/pediatric cohort. The role of HARP is to provide overall project coordination, administration, data and biospecimen management, research protocols and procedures development and implementation, biostatistics/data analytics support; as well as laboratory (including multi-omics) and biorepository expertise for development of this unique intergenerational cohort and resource. HARP, in collaboration with the consortium of clinical centers, will lead the scientific development, pragmatic implementation, and expert conduct of the hypothesis-driven protocols that will permit the establishment of the severe Hemophilia A intergenerational cohort, utilization of some of the cohort longitudinal data and biospecimens, and establishment of a shareable resource for the scientific community.
| Federal Grant Title: | An Intergenerational Precision Medicine Research Program for the Study of Factor VIII Immunogenicity in Severe Hemophilia A: Hemophilia A Analytical Cohort Research Program (UG3/UH3 Clinical Trial Not Allowed) |
| Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
| Grant Categories: | Health |
| Type of Opportunity: | Discretionary |
| Funding Opportunity Number: | RFA-HL-22-004 |
| Type of Funding: | Cooperative Agreement |
| CFDA Numbers: | 93.839 |
| CFDA Descriptions: | Information not provided |
| Current Application Deadline: | October 19th, 2021 |
| Original Application Deadline: | October 19th, 2021 |
| Posted Date: | September 9th, 2021 |
| Creation Date: | September 9th, 2021 |
| Archive Date: | November 24th, 2021 |
| Total Program Funding: | |
| Maximum Federal Grant Award: | |
| Minimum Federal Grant Award: | |
| Expected Number of Awards: | |
| Cost Sharing or Matching: | No |
| Last Updated: | September 9th, 2021 |
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-22-004.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires. - Similar Government Grants
- • New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional)
- • Limited Competition: Sickle Pan-African Research Consortium Clinical Coordinating Center (...
- • Sickle Pan-African Research Consortium Collaborative Sites (U01 Clinical Trial Optional)
- • Limited Competition: Sickle Africa Data Coordinating Center (U24 Clinical Trial Optional)
- • BLOODSAFE: Research to enhance availability of safe blood for patients with severe anemia ...
- • Improved Therapy for Hemophilia and Hereditary Bleeding Disorders
- • Clinical Hematology Research Career Development Program (K12)
- • Molecular Mechanisms Underlying Diamond-Blackfan Anemia and Other Congenital Bone Marrow F...
- More Grants from the National Institutes of Health
- • NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)
- • NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)
- • Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Olde...
- • NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies w...
- • Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental S...